Loading…
← CockpitCompetitor Analysis › 301096.SZ Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class AOpen in the cockpit ↗

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A301096.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 24
Mkt cap
$602M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$20.3M
20-day average traded
Fwd P/E
54.0×
forward earnings
ROIC−WACC
-10.2 pp
WACC 8.6%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥37.61
1D-2.7%
1W-6.5%
1M-12.9%
3M-23.8%
6M-37.8%
YTD-34.2%
1Y-35.8%
ATR %7.1%
52w lowhigh51.3% off high

What Hangzhou Bio-Sincerity Pharma-Tech does

Employees: 1,412

Hangzhou Bio-Sincerity Pharma-Tech at a glance

Size Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $602M, the 3234th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥37.61 on 18 Nov 2026.

Performance Over six months the shares fell 37.8%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +2.6%); the operating margin is -29.9% (peer median 4.4%).

Valuation It trades at 54.0× forward earnings against a peer median of 11.4× (2nd most expensive of 8).

Capital Return on invested capital runs 10.2 points below its cost of capital (8.6% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 75301096.SZ 59
Six months, rebased to 100: Hangzhou Bio-Sincerity Pharma-Tech against the median of its 20 peers (local-currency closes).

Hangzhou Bio-Sincerity Pharma-Tech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥618MCN¥678MCN¥802MCN¥1.02BCN¥607M
Revenue growth—-15%-21%+68%—
Gross profitCN¥260MCN¥186MCN¥330MCN¥614MCN¥381M
EBITDAn/aCN¥74.7MCN¥101MCN¥353MCN¥197M
Net income-CN¥178M-CN¥90.4M-CN¥52.7MCN¥272MCN¥194M
Free cash flow-CN¥71.3M-CN¥250M-CN¥590M-CN¥598M-CN¥332M
Capital expenditureCN¥85.8MCN¥97.9MCN¥395MCN¥689MCN¥592M
Total debtCN¥950MCN¥884MCN¥724MCN¥474MCN¥36.6M

Quarterly statements and history in the cockpit →

Hangzhou Bio-Sincerity Pharma-Tech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%300233DBV600976IMMX603567002940300194300147ORCHPHARMA4105OLMA301211CGEM603439BCAX2157301096.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hangzhou Bio-Sincerity Pharma-Tech is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×25×50×75×600976185750603567ORCHPHARMA6034392157301096.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hangzhou Bio-Sincerity Pharma-Tech is the large dot.

Hangzhou Bio-Sincerity Pharma-Tech competitors and peer comparison

How Hangzhou Bio-Sincerity Pharma-Tech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hangzhou Bio-Sincerity Pharma-Tech against its 20 peers (data as of 18 Nov 2026)
Measure301096.SZPeer medianRank in peer set
1-month return-12.9%-11.8%7th lowest of 20
6-month return-37.8%-26.6%8th lowest of 20
Distance from 52-week high-51.3%-43.9%9th lowest of 20
Revenue growth (TTM)+4.7%+2.6%6th highest of 15
Operating margin-29.9%4.4%3rd lowest of 14
Forward P/E54.0×11.4×2nd most expensive of 8
ROIC minus cost of capital-10.2 pp-4.0 pp4th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a

Questions

Which companies are Hangzhou Bio-Sincerity Pharma-Tech's closest peers?
The cockpit's peer set: Shandong Jincheng Pharmaceutical (300233.SZ), DBV Technologies (DBV.PA), JIANMIN PHARMACEUTICAL (600976.SS), Immix Biopharma (IMMX), Chongkundang (185750.KS), Luoxin Pharmaceuticals Group Stock (002793.SZ), Achieve Life Sciences (QUIT), HeiLongJiang ZBD Pharmaceutical (603567.SS).
Is Hangzhou Bio-Sincerity Pharma-Tech expensive compared with its peers?
On forward p/e it trades at 54.0× against a peer median of 11.4×, 2nd most expensive of 8 in its peer set.
How has Hangzhou Bio-Sincerity Pharma-Tech stock performed?
Over six months to 18 Nov 2026 the shares returned -37.8% against -26.6% for the median peer; over one year -35.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.